Payment overview · 2025
General Payments
$124.58
4 reported records · 2 companies
Healthcare provider profile · identity verified
Vivekkumar V Dasondi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GALLOWAY, NJ · NPI 1528129509
Verified facts
What the public records show
CMS Open Payments records show Vivekkumar V Dasondi, MD received $124.58 in general payments during 2025 across 4 reported records.
Procept Biorobotics Corporation accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Procept Biorobotics Corporation | Unresolved — no canonical attribution shown | $70.22 | 56.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.36 | 43.6% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.58 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AQUABEAM ROBOTIC SYSTEM Normalized: aquabeam robotic system |
Device | Procept Biorobotics Corporation | $70.22 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $54.36 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 635 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 122 |
| Losartan Potassium | Losartan Potassium | 416 | 108 |
| Famotidine | Famotidine | 345 | 93 |
| Metformin Hcl | Metformin Hcl | 303 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 83 |
| Eliquis | Apixaban | 263 | 43 |
| Gabapentin | Gabapentin | 234 | 63 |
| Furosemide | Furosemide | 220 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 67 |
| Carvedilol | Carvedilol | 197 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 49 |
| Omeprazole | Omeprazole | 193 | 66 |
| Alprazolam | Alprazolam | 189 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 56 |
| Januvia | Sitagliptin Phosphate | 161 | 19 |
| Divalproex Sodium | Divalproex Sodium | 159 | 20 |
| Potassium Chloride | Potassium Chloride | 144 | 40 |
| Prednisone | Prednisone | 144 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 89 |
| Lisinopril | Lisinopril | 131 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 22 |
| Buspirone Hcl | Buspirone Hcl | 127 | 27 |
| Sertraline Hcl | Sertraline Hcl | 126 | 32 |
| Azelastine Hcl | Azelastine Hcl | 116 | 72 |
| Tramadol Hcl | Tramadol Hcl | 110 | 21 |
| Donepezil Hcl | Donepezil Hcl | 106 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 14 |
| Ezetimibe | Ezetimibe | 102 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 29 |
| Mirtazapine | Mirtazapine | 90 | 20 |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 72 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 38 |
| Lorazepam | Lorazepam | 70 | 13 |
| Allopurinol | Allopurinol | 69 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 16 |
| Meloxicam | Meloxicam | 61 | 26 |
| Montelukast Sodium | Montelukast Sodium | 60 | 17 |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Finasteride | Finasteride | 57 | 11 |
| Enalapril Maleate | Enalapril Maleate | 56 | 15 |
| Atenolol | Atenolol | 55 | suppressed |
| Levetiracetam | Levetiracetam | 55 | 12 |
| Diazepam | Diazepam | 53 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 18 |
| Repaglinide | Repaglinide | 51 | 18 |
| Ramipril | Ramipril | 50 | 14 |
| Glimepiride | Glimepiride | 47 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 21 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Propranolol Hcl | Propranolol Hcl | 39 | 11 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 14 |
| Lokelma | Sodium Zirconium Cyclosilicate | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 11 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | 11 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 24 | 19 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 12 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Acetylcysteine | Acetylcysteine | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.58 · 4 records | Procept Biorobotics Corporation | AQUABEAM ROBOTIC SYSTEM, TEFLARO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error